SPON2在甲状腺乳头状癌中的表达及其临床意义

doi:10.3969/j.issn.1004-616x.2023.01.002

Abstract

Abstract: OBJECTIVE: To investigate expression of spondin 2 (SPON2) in papillary thyroid carcinomas (PTC) and its clinical significance. METHODS: Seven fresh surgical specimens of PTC and adjacent tissues were collected. real-time quantitative PCR (qPCR) was used to detect mRNA expression of SPON2 in the tissues. From 2019-2020，68 cases of PTC paraffin specimens were collected from the Department of Pathology and expression of SPON2 protein in the specimens were detected using the immunohistochemical SP method. Prognostic relationships between SPON2 mRNA expression levels and thyroid cancers were evaluated using the Kaplan Meier-Plotter database. Relationships between SPON2 mRNA expression levels and clinical stages were analyzed using the GEPIA database. Relationships between SPON2 mRNA expression levels and thyroid cancer immune cells were analyzed using the TIMER database. RESULTS: The qPCR results showed that the mRNA expression levels of SPON2 were significantly higher in PTC tissues (1.705 ± 0.724) than in paraneoplastic tissues (0.929±0.278) (P=0.036). Immunohistochemical results showed that SPON2 protein was expressed in the cytoplasm and the extracellular matrix， and their expressions were significantly higher in PTC than in its paracancerous tissues (P<0.001). Analysis of the GEPIA database revealed that differences in SPON2 mRNA expression correlated with clinical stages of the cancers (P=0.002). The Kaplan Meier-Plotter database showed that， in 502 thyroid cancer cases， prognostic survival was worse in patients with high SPON2 mRNA expressions than with low expressions (P=0.026). TIMER database analysis showed that SPON2 mRNA expressions did not correlate significantly with thyroid cancer tumor purity (P=0.135)， but positively and significantly correlated with B cells， CD8⁺ T cells， CD4⁺ T cells， macrophages， neutrophils， dendritic cell infiltration，and the M2 macrophage markers CD68，CD163，and CD206 (P<0.001). CONCLUSION: SPON2 was highly expressed in PTC cancer tissues. Thyroid cancer patients with high SPON2 expressions had poor prognosis. SPON2 might have promoted progression of thyroid cancers through M2 macrophages and other immune cells. SPON2 may be a new marker for diagnosis of thyroid cancers， for evaluating clinical stages and prognosis of the cancers and for therapeutic target.

Key words: SPON2, thyroid cancer, papillary thyroid carcinoma, immune cells, prognosis, immunohistochemical

CLC Number:

R736.1

HU Xueyi, SHEN Feng, WU Lun, SU Caiwu, WEI Jian. SPON2 expression in papillary thyroid carcinomas and its clinical significance[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(1): 9-14.

References

[1] LI Y Z, PIAO J M, LI M. Secular trends in the epidemiologic patterns of thyroid cancer in China over three decades:an updated systematic analysis of global burden of disease study 2019 data[J]. Front Endocrinol (Lausanne), 2021, 12:707233.
[2] WANG J Y, YU F F, SHANG Y N, et al. Thyroid cancer:incidence and mortality trends in China, 2005-2015[J]. Endocrine, 2020, 68(1):163-173.
[3] KIM J, GOSNELL J E, ROMAN S A. Geographic influences in the global rise of thyroid cancer[J]. Nat Rev Endocrinol, 2020, 16(1):17-29.
[4] FAGIN J A, WELLS S A Jr. Biologic and clinical perspectives on thyroid cancer[J]. N Engl J Med, 2016, 375(11):1054-1067.
[5] 施晓婧, 左云, 吕燕, 等. 细胞外基质蛋白spondin2在人胃癌组织中的表达及其临床意义[J]. 中国肿瘤生物治疗杂志, 2017, 24(11):1304-1308.
[6] 薛刚, 孙新民, 林旭, 等. KCNK5双孔钾通道蛋白在甲状腺乳头状癌中的表达及临床意义[J]. 山东大学耳鼻喉眼学报, 2021, 35(4):64-69.
[7] 张丽, 黄瑛. PDPN基因在胰腺癌组织中的表达情况及与预后的关系[J]. 中国卫生检验杂志, 2021, 31(11):1340-1342, 1346.
[8] 徐瑞, 张岩. 蛇床子素治疗乳腺癌潜在机制的生物信息学分析[J]. 中华肿瘤防治杂志, 2021, 28(13):980-987.
[9] 李竹林, 王振军, 赵博, 等. 结直肠癌细胞外基质与癌细胞上皮-间质转化和分期的相关性[J]. 中华肿瘤防治杂志, 2016, 23(16):1076-1080.
[10] FEINSTEIN Y, KLAR A. The neuronal class 2 TSR proteins F-spondin and Mindin:a small family with divergent biological activities[J]. Int J Biochem Cell Biol, 2004, 36(6):975-980.
[11] JIA W, LI H, HE Y W. The extracellular matrix protein mindin serves as an integrin ligand and is critical for inflammatory cell recruitment[J]. Blood, 2005, 106(12):3854-3859.
[12] LU H M, FENG Y, HU Y L, et al. Spondin 2 promotes the proliferation, migration and invasion of gastric cancer cells[J]. J Cell Mol Med, 2020, 24(1):98-113.
[13] 曹莉旻, 李艳, 赵秋菊, 等. 肺癌组织中FOXK1、SPON2蛋白表达变化及意义[J]. 山东医药, 2019, 59(13):23-26.
[14] 熊晶, 邓辉, 王渝, 等. MACC1及其靶蛋白SPON2在乳腺癌中的表达及与预后的关系[J]. 现代肿瘤医学, 2018, 26(24):3954-3958.
[15] CHANDRASINGHE P, STEBBING J, WARUSAVITARNE J. The MACC₁-SPON₂ axis:a new biomarker and therapeutic target in colorectal cancer[J]. Oncogene, 2017, 36(11):1474-1475.
[16] KANG H G, KIM W J, NOH M G, et al. SPON₂ is upregulated through Notch signaling pathway and promotes tumor progression in gastric cancer[J]. Cancers, 2020, 12(6):1439.
[17] 黄滨, 王丽萍, 林振孟. 脊椎蛋白2在胃癌中的表达及临床意义[J]. 中国医药导报, 2021, 18(20):16-20, 197.
[18] 马慧敏, 于猛, 黄后宝, 等. SPON2基因在肾透明细胞癌中的表达与临床意义[J]. 皖南医学院学报, 2020, 39(5):425-428.
[19] XU Z J, GU Y, WANG C Z, et al. The M2 macrophage marker CD206:a novel prognostic indicator for acute myeloid leukemia[J]. OncoImmunology, 2020, 9(1):1683347.
[20] REN C X, LENG R X, FAN Y G, et al. Intratumoral and peritumoral expression of CD68 and CD206 in hepatocellular carcinoma and their prognostic value[J]. Oncol Rep, 2017, 38(2):886-898.
[21] SHABO I, SVANVIK J. Expression of macrophage antigens by tumor cells[M]//Advances in Experimental Medicine and Biology. Dordrecht:Springer Netherlands, 2011:141-150.
[22] EGEBLAD M, NAKASONE E S, WERB Z. Tumors as organs:complex tissues that interface with the entire organism[J]. Dev Cell, 2010, 18(6):884-901.
[23] KHAWAR I A, KIM J H, KUH H J. Improving drug delivery to solid tumors:priming the tumor microenvironment[J]. J Control Release, 2015, 201:78-89.
[24] XIAO H, GUO Y, LI B, et al. M2-like tumor-associated macrophage-targeted codelivery of STAT6 inhibitor and IKKβ siRNA induces M2-to-M1 repolarization for cancer immunotherapy with low immune side effects[J]. ACS Cent Sci, 2020, 6(7):1208-1222.
[25] HUANG C M, OU R Z, CHEN X N, et al. Tumor cell-derived SPON2 promotes M2-polarized tumor-associated macrophage infiltration and cancer progression by activating PYK2 in CRC[J]. J Exp Clin Cancer Res, 2021, 40(1):304.
[26] 侯飞, 吕娟, 杨志贤, 等. 肿瘤相关巨噬细胞在甲状腺乳头状癌中的分布及临床意义的初探[J]. 中国肿瘤临床, 2021, 48(12):609-613.
[27] COULIE P G, VAN DEN EYNDE B J, VAN DER BRUGGEN P, et al. Tumour antigens recognized by T lymphocytes:at the core of cancer immunotherapy[J]. Nat Rev Cancer, 2014, 14(2):135-146.
[28] FERRARI S M, FALLAHI P, GALDIERO M R, et al. Immune and inflammatory cells in thyroid cancer microenvironment[J]. Int J Mol Sci, 2019, 20(18):4413.

SPON2 expression in papillary thyroid carcinomas and its clinical significance

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	XU Hao, HU Bichuan, ZOU Wei, DUAN Yabin. Identification of prognostic factors among patients with stage Ⅲ gastric cancer undergoing radical resection [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(1): 30-36.
[2]	LI Ziyao, ZHANG Haiping, MADINIYET·Niyaz, JULATI·Ainiwaer, ZHANG Liwei, EDRIS·Awut. Clinicopathological significance of cystatin 6 protein expression in Kazakh esophageal squamous cell carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(6): 429-433,438.
[3]	YU Yunliang, WANG Lili, LI Ting, FENG Jiankai. Correlations among P2RX1,prognosis and immune cells infiltration in lung adenocarcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(5): 353-360,365.
[4]	ZHANG Haizhi, WEN Xiaofen, HUANG Binliang, LIN Hui, XUE Wenwu, ZENG De, LIN Danxia. Expression and clinical significance of SLC50A1 in breast carcinomas [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(5): 373-377.
[5]	ZHANG Yuling, LIU Ditian, CHEN Chunfa. Impact of CD68 macrophage infiltration on prognosis in primary small cell esophageal carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(4): 279-283.
[6]	WANG Xujuan, LUO Yongxin, LI Chenqiang, WANG Rujin, ZHENG Tingting. Predictive values of preoperative laboratory indices dNLR, SII and CRP/ALB on recurrences and metastases in breast cancer patient [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(4): 284-288,323.
[7]	LIANG Feng, ZHANG Wei, LI Fei, WANG Shengjie, DU Yujing, ZHANG Yingchun. Expressions of lncRNA CASC9 in colorectal cancer and its relationship with clinical prognosis [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(2): 110-113.
[8]	PENG Youbin, LIN Hao, LI Ming, HUANG Haihua. Expression of TPX2 and its clinicalsignificance in non-muscle-invasive bladder cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(1): 30-34.
[9]	JIAO Wenpeng, HOU Lin, CUI Meijuan, JIAO Wenjing, MA Ming, ZHANG Jinyan. Expression of miR-93-5p and miR-106b-5p in alcohol-related liver cancer and its clinical significance [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(6): 430-434.
[10]	GAO Xiaobin, WU Xueliang, WANG Shengjie, SUN Guangyuan, WANG Wenjing, LIANG Feng, ZHAO Yifeng, LIU Zhenxian, ZHANG Yingchun. Expression of TRIM59 and its correlations with clinicopathological features in colorectal cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(6): 446-450.
[11]	JIAO Wenjing, ZHANG Jinyan, MA Ming, GUO Xiujuan, FENG Junhua, SHAO Junguo, JIAO Wenpeng. Expression and clinical significance of MTDH and FoxM1 in hepatocellular carcinomas [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(5): 349-353,359.
[12]	ZHANG Shimin, ZHAO Ruijun. Expression of protein tyrosine phosphatase receptor J in breast cancer tissues and its relationship with clinical prognosis [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 276-279,285.
[13]	LIU Xiaoxia, LI Weixia, LI Zhijia, SU Zhenjun, DUAN Xiaohui, HAN Weiwen, WANG Yunxiao, HE Xiaolei, Lu Linlin, JIA Jinhai. Correlations between glutathione peroxidase in serum and clinicopathological outcomes of advanced non-small cell lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 286-290,295.
[14]	ZHANG Yuling, WU Jundong, PANG Dongyue, CHEN Chunfa. Changes of Ki67 expression before and after neoadjuvant chemotherapy as a predictor for therapeutic response and rognosis in breast cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 230-235,245.
[15]	SHI Hailin, HE Tianji, LIU Feng, CAI Menghui, GE Bo. Prognostic value of TCGA-database mutation burden in muscle-invasive bladder cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 430-437,443.